Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 478.70M P/E - EPS this Y 33.50% Ern Qtrly Grth -
Income -308.48M Forward P/E -2.24 EPS next Y 10.20% 50D Avg Chg -30.00%
Sales 15.84M PEG - EPS past 5Y - 200D Avg Chg -48.00%
Dividend N/A Price/Book 1.36 EPS next 5Y - 52W High Chg -64.00%
Recommedations 2.00 Quick Ratio 8.44 Shares Outstanding 47.84M 52W Low Chg 8.00%
Insider Own 9.88% ROA -21.72% Shares Float 37.84M Beta 0.96
Inst Own 81.69% ROE -90.24% Shares Shorted/Prior 2.48M/4.48M Price 10.06
Gross Margin - Profit Margin - Avg. Volume 917,950 Target Price 20.85
Oper. Margin -916.34% Earnings Date May 7 Volume 1,168,323 Change -5.27%
About uniQure N.V.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V. News
03/13/24 13 Best Biotech Stocks To Buy Under $20
03/03/24 uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates
02/29/24 uniQure NV CEO Matthew Kapusta Sells 27,904 Shares
02/28/24 uniQure NV (QURE) Reports 2023 Financial Results Amid Strategic Reorganization
02/28/24 UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
02/28/24 uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
02/27/24 12 Best Medical Stocks to Buy Under $10
07:15 AM Investors still aren’t sold on UniQure’s gene therapy for Huntington’s
07:05 AM uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
12/11/23 CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
12/10/23 12 Best Genomics Stocks To Buy Now
12/08/23 uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/02/23 Shareholders in uniQure (NASDAQ:QURE) are in the red if they invested three years ago
11/29/23 uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
11/14/23 3 Micro-Cap Stocks That Could Be Moonshots
11/11/23 Calculating The Fair Value Of uniQure N.V. (NASDAQ:QURE)
11/08/23 Wall Street Analysts Believe uniQure (QURE) Could Rally 405.37%: Here's is How to Trade
11/07/23 UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
11/07/23 uniQure NV (QURE) Reports Q3 2023 Earnings: Net Loss Widens, Cash Position Strengthens
11/07/23 uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
QURE Chatroom

User Image Stu52 Posted - 1 day ago

$QURE BFD !!!

User Image Redposition Posted - 1 day ago

$QURE 16:00:06 $4.67 304,962

User Image Stu512 Posted - 4 days ago

$QURE More lows ahead !!! Board members leaving, Matt can’t be found , hahaha

User Image Stu52 Posted - 4 days ago

$QURE Need you need me here daily ??

User Image Stu52 Posted - 4 days ago

$QURE FEAR OF BEING SUED BY SHAREHOLDERS FOR NOT FIRING MATT KAPUSTA. her options are worthless , Matt failed to perform his fiduciary duty to the Board and shareholders, she wants out

User Image Redposition Posted - 6 days ago

$QURE Paula Soteropoulos, a non-executive director of gene therapy company uniQure N.V. (NASDAQ:QURE), has decided not to stand for re-election at the upcoming annual shareholder meeting. The company, known for its pioneering work in developing treatments for rare diseases, announced her departure in a recent SEC filing.

User Image Redposition Posted - 6 days ago

$QURE Paula Soteropoulos, a non-executive director of gene therapy company uniQure N.V. (NASDAQ:QURE), has decided not to stand for re-election at the upcoming annual shareholder meeting. The company, known for its pioneering work in developing treatments for rare diseases, announced her departure in a recent SEC filing. Soteropoulos, whose term will conclude at the 2024 annual meeting, has been part of uniQure's board of directors for an unspecified period. The company disclosed on Monday that her decision to leave is not due to any disagreements with uniQure's management, operations, or practices. The board of directors has not yet announced a successor or detailed the process for filling the impending vacancy. The announcement in the SEC filing did not elaborate on Soteropoulos's future endeavors or whether she will maintain a relationship with the company in any other capacity. his transition on its

User Image Redposition Posted - 1 week ago

$QURE where are you Stu today 🤔

User Image prevclose Posted - 1 week ago

$QURE Interesting. Qure calls are on the active list for calls.

User Image Stu52 Posted - 1 week ago

$QURE SSDD …Matt still exists, that monkey on his back will never go away .. Monkey’s name : FAILURE

User Image Stu52 Posted - 1 week ago

$CADL. Most hope I am wrong !!! $CCL -ers waiting for $20 for 2 years now , lol…and March is their best quarter !!! That’s done…$Blue , still falling apart and I called that. $Sava from $146 to 13 last October 13 2023 and 2 dilutions ..and $qure $15 to $4 after being at $54 , called that, due to CEO then there is many more , but you get the picture even $ESPR I called to “ failure to launch” on mere labels , lol !!

User Image Stu52 Posted - 1 week ago

$QURE ..you have not been right here yet, lol

User Image Stu52 Posted - 1 week ago

$QURE

User Image Stu52 Posted - 1 week ago

$QURE got to love Matt screwed his own employees with options at$6.20 cents, lol in November. I’m sure most said F U and left .

User Image Stu52 Posted - 1 week ago

$QURE Wanted the F out

User Image Redposition Posted - 1 week ago

$QURE AH 1 transaction 279.7K @ $5.15 🤔

User Image prevclose Posted - 2 weeks ago

$QURE Goldman price target $28

User Image Stu52 Posted - 2 weeks ago

$QURE hell that was known when he convinced the Board to sell the drug to CSL Behring and became their $horse making the product and just getting a TINY slice of the sales. That day, was dooms day for QURE !!! Now they are just another Gm, FORD, Tesla, factory making a drug and handing it over to CSL, for Pennies on what CSL will charge ! Meanwhile, Matt gets a salary and doesn’t have to produce sales like he did as a stock broker !! He managed to get himself on a welfare train !!! Express QURE

User Image Redposition Posted - 2 weeks ago

$QURE CEO totally incompetent. Can't answer analysts questions this is why always hiding and no conference call after earnings release !

User Image Stu52 Posted - 2 weeks ago

$QURE @buyandsold Loving your Matt now ! You said $12 SOON …you forgot who is CEO !

User Image Stu52 Posted - 2 weeks ago

$QURE CEO Matt Kapusta …Next The Monkey will be your CEO.

User Image Stu52 Posted - 03/29/24

$QURE here I’ll post your commentary

User Image Stu52 Posted - 03/29/24

$QURE At @buyandsold …where is your statement to me , lol, for everyone to read of “ QURE will be at $12 in 90 days “ lol …. A better statement more precise is “July 4th is coming once again this year, after July 3rd “ Your boy Matt Kapusta , CEO of this $hit company, is nothing more than a washed up ex stock broker who peddled Enron and Valeant to clients.

User Image Stu52 Posted - 03/28/24

$QURE DONE , hahahaha …how about QURE is DONE @$5 …that’s the reality of having an ex stock broker as a CEO….cluesless sales people selling $hit in brown paper bags

User Image DesertDweller93 Posted - 03/25/24

@Inthe512 You're right, it is higher with $pdsb only at 26% tutes but it still shows the tutes don't always know what is happening with small cap stocks, or even big caps. Hell, if WS knew, $labp wouldn't have closed Friday under $8 only to get bought out for $20+CVR potentially worth another $11. The other comparison is $qure which currently has tute ownership of >83% and yet is down >90% from its high. This week should reveal a lot, or at least I hope it does. I prefer to invest on data than on trying to read institutional ownership or charts. The worrisome thing for me is definitely the cash position but that will be fixed with lucrative partnership or secondary. I prefer partnership but we should see soon.

User Image Stu52 Posted - 03/25/24

$QURE What is the ex stock broker’s story today ??? Trump won a golf match, lol ..he was the Judge , lol. ..ahh, I get it, so is Matt K , the judge here…the jury says “ you are fired” “ you are incompetent “

User Image Stu52 Posted - 03/24/24

$QURE Haha..I didn’t read “cure “ in their latest puff piece…$20

User Image buyandsold Posted - 03/23/24

$QURE Cure Huntingdons. $200. Done.

User Image Stu52 Posted - 03/22/24

$QURE …gee, may 2023 and I’m the idiot !!!! And QURE is now at $5,almost not marginable and and and KICKED OUT OF THE XBI and @FundingMyBoat , would have you BUYING THIS POS !!!! oh boy ..BAGGED , lol…YOU LOSE

User Image FundingMyBoat Posted - 03/22/24

$QURE I see STFU52 the ST village idiot is still meeting his life long goal of being an internet troll on a stock forum. A true winner!

Analyst Ratings
Mizuho Neutral Mar 4, 24
HC Wainwright & Co. Buy Mar 1, 24
Goldman Sachs Neutral Feb 29, 24
HC Wainwright & Co. Buy Jan 19, 24
RBC Capital Outperform Jan 16, 24
Cantor Fitzgerald Overweight Dec 20, 23
Mizuho Neutral Dec 19, 23
Goldman Sachs Buy Nov 8, 23
HC Wainwright & Co. Buy Aug 2, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dolmetsch Ricardo President, R&D President, R&D Sep 18 Sell 7.46 5,841 43,574 163,404 09/20/23
CALOZ PIERRE Chief Operating Offi.. Chief Operating Officer Jul 10 Sell 11.36 15,117 171,729 95,098 07/12/23
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Mar 07 Sell 21.36 585 12,496 90,381 03/09/23
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Jul 27 Option 5.31 37,762 200,516 122,554 07/29/22
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Jul 27 Sell 25 37,762 944,050 95,196 07/29/22
CALOZ PIERRE Chief Operating Offi.. Chief Operating Officer Jun 16 Sell 13.21 7,575 100,066 64,511 06/21/22
KLEMT CHRISTIAN Chief Financial Offi.. Chief Financial Officer Jun 16 Sell 13.20 1,687 22,268 104,688 06/21/22
POST LEONARD E Director Director Feb 28 Sell 16.64 795 13,229 3,121 03/02/22
Kaye Jack Director Director Feb 28 Sell 16.76 600 10,056 19,003 03/02/22
Springhorn Jeremy P. Director Director Feb 28 Sell 16.7 602 10,053 10,877 03/02/22
Meek David D. Director Director Feb 28 Sell 16.7 602 10,053 7,380 03/02/22
Balachandran Madhavan Director Director Feb 28 Sell 16.7 602 10,053 10,877 03/02/22
Soteropoulos Paula Director Director Feb 28 Sell 16.87 596 10,055 7,302 03/02/22
Dolmetsch Ricardo President, R&D President, R&D Feb 28 Sell 16.68 1,484 24,753 122,325 03/02/22
KLEMT CHRISTIAN Chief Financial Offi.. Chief Financial Officer Feb 28 Sell 16.8 4,075 68,460 106,375 03/02/22
Gut Robert Director Director Jan 26 Sell 18.12 2,348 42,546 35,153 01/28/22
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Jan 26 Sell 18.02 2,945 53,069 63,697 01/28/22
KLEMT CHRISTIAN Chief Financial Offi.. Chief Financial Officer Jan 26 Sell 18.03 3,963 71,453 66,820 01/28/22
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Jan 26 Sell 18.1 10,901 197,308 245,676 01/28/22
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Dec 15 Option 5.31 6,000 31,860 72,642 12/15/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Dec 15 Sell 27.9 6,000 167,400 66,642 12/15/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Sep 16 Sell 36.32 6,000 217,920 68,871 09/16/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Sep 16 Option 5.31 6,000 31,860 74,871 09/16/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations May 18 Option 5.31 6,000 31,860 74,871 05/18/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations May 18 Sell 31.66 6,000 189,960 68,871 05/18/21
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Dec 21 Option 7.53 12,501 94,133 277,738 12/21/20
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Nov 20 Option 7.53 3,216 24,216 283,780 11/20/20
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Nov 20 Sell 43.93 10,313 453,050 273,467 11/20/20
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Sep 18 Sell 41.28 7,500 309,600 285,814 09/18/20